- HHS agency launches $139.4M behavioral health research initiative
- Dell gifts push UT Austin support past $1B, fund new medical campus
- Hospital telehealth adoption by state
- CMS pauses weight-loss BALANCE model for Medicare
- Mayo Clinic backs virtual biomarker startup in $4.9M investment
- CMS to require state audits of all providers accepting Medicaid
- Texas ASC completes 1st artery embolizations with Regent Surgical platform
- Why independent dentistry is ready for a comeback
- UnitedHealthcare’s ‘deliberate trade-off’ for margin recovery
- Surgeons’ sex ruled out as driver of disparities in cardiac surgery: Study
- VCU Health creates new marketing leadership role
- Optum revenue hits $63.7B in Q1
- Wellstar CEO: Keeping care local while building across the Southeast
- What is ibogaine? 4 things to know
- Lexington Health names new CIO
- How Tenet turned a hospital company into the country’s largest ASC operator: 7 things to know
- What dentists need to know about the growing use of AI in healthcare
- 3 GI leaders keeping their practices independent in 2026
- 69% of DSOs plan to boost acquisitions in 2026: Report
- Minnesota ASC sees 1st Vanquish procedure in Midwest
- NADP appoints 1st dentist to permanent position
- Texas behavioral health provider reports breach affecting 285,000
- 5 new workforce statistics for dentists to know
- Heartland Dental to open $660K Florida office
- Heartland Dental adds RCM solutions to network
- Physician Partners of America adds another anesthesiologist
- Nonprofits to merge into national suicide prevention organization
- Community Health Systems reports low volumes, earnings dip for Q1 2026
- Prenatal medications linked to increased autism risk: 4 study notes
- What’s new with Ascension?
- Psych hospital’s security change draws scrutiny amid patient assaults
- 5 orthopedic leaders shaping ASC growth
- What 3 recent CON debates mean for the ASC industry
- The DSO de novo boom
- Children’s Activity Cubes Recalled Over Choking Hazard Risk
- What is ibogaine? 4 things to know
- Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso
- Rush to open 60,000-square-foot Chicago wellness center
- 'Don't be a wimp,' Mark Cuban tells lawmakers hesitant to break up PBMs
- VideaHealth undergoes rebrand, extends to private practices
- Study Finds AI Chatbots Can Give Misleading Health Advice
- Former Surgeon General Backs CDC Nominee, But Questions Remain on Vaccines
- Listen to the Latest ‘KFF Health News Minute’
- Cantaloupes Recalled in Four States Due to Salmonella Risk
- Keynote Remarks at The Economic Club of Washington
- Merger to create nation's largest suicide prevention nonprofit
- Oz previews new plan to push states toward revalidating Medicaid providers
- Pfizer's strategy head Andrew Baum to step down following brief tenure: reports
- Covera Health, Medmo combine to create end-to-end diagnostic imaging platform
- The Oral GLP-1 Tracker: Following the launch trajectories of Lilly’s Foundayo, Novo’s Wegovy pill
- Service Dogs Perform Tasks Akin To Human Caregivers, Researchers Say
- A Third Of Young Adults Are Couch Potatoes, Their Parents Say
- Powerful Antibiotic Combo Not Necessary For Simple Sinus Infections, Study Shows
- Black Women Hit Hardest By Pandemic-Related Rise In Pregnancy-Related Deaths
- Smoking, Vaping Weed Increases Risk Of Asthma Attacks Among Young Adults, Study Finds
- Less-Dangerous Painkillers, Gabapentinoids, Still Have High Risk For Drug Interactions
- AstraZeneca eyes 5th Ultomiris indication after kidney disease trial win
- In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
- Listen: Cheap Health Insurance Isn’t Always Cheap
- Real Estate Investors Profit From Long-Term Care While Residents Languish
- Democrats Demand Trump Administration Halt Plan To Collect Federal Workers’ Health Data
- UnitedHealth Group spotlights AI investments as part of operational turnaround
- ECRI spins out healthcare supply chain division into Staritas, backed by PE firm Accel-KKR
- UCB partners with Myasthenia Gravis Foundation of America on meal program targeting nutrition deserts
- Indiana University Southeast earns counseling accreditation
- Ohio safety-net provider to acquire behavioral health organization
- Replimune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection
- Connecticut dentists among growing number of non-hospital clinicians suing patients over medical debt: Report
- 3 in 10 adults turn to digital tools for mental health: 4 study notes
- Statement on the Amendments to Form PF
- Update on the SEC’s Work Toward Treasury Clearing Implementation
- 'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilot
- “PF” Stands for Please Fix: Statement on the Proposed Amendments to Form PF
- A look inside Highmark and Spring Health's mental well-being partnership
- CVS, Mass General Brigham primary care deal would increase annual care spending by $40M, report predicts
- Beyond Reporting: Realizing Continuous Safety Surveillance for Medical Devices
- Beyond Reporting: Realizing Continuous Safety Surveillance for Medical Devices
- Safeguarding Scientific Publishing from AI Hallucinations and Fabricated Citations
- Safeguarding Scientific Publishing from AI Hallucinations and Fabricated Citations
- AIDS Relief Program Sees Drops in Testing and Diagnoses After Disruptions
- Baby Food Recalled After Rat Poison Discovered in Jar
- Report Finds Drug Prices Rising Despite Trump Pricing Deals
- Trump Backs Psychedelic Research
- Styker Adds IVL Technology to Peripheral Vascular Portfolio with Amplitude Acquisition
- Styker Adds IVL Technology to Peripheral Vascular Portfolio with Amplitude Acquisition
- Hippocratic AI rolls out 2 new tools aimed at expanding clinical access, improving nurse workflow
- In Connecticut, doctors now sue patients most over medical bills, surpassing hospitals
- Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike
- Physician burnout falls for third year in 2025 to 42%, AMA data shows
- Naloxone's OD-Reversing Powers Challenged By Today's Opioids, Tests Show
- Extra Antibiotic Doesn't Reduce Infection Risk During Surgery To Fix Complex Fractures, Trial Finds
- Clinical Trial Suggests Two Simple Ways To Fight Chemo-Related Brain Fog
- E-Cigarette Taxes Won't Necessarily Cause An Increase In Smoking, Study Says
- Dreams Affect Your Morning Mood In Surprising Ways, Study Finds
- Weed Blunts Brain Development In Teens
- Genentech shifts Hemlibra marketing focus to patient stories as competition approaches
- An Arm and a Leg: The Accidental Architect of America’s Drug Patent Problem
- In Connecticut, Doctors Now Sue Patients Most Over Medical Bills, Surpassing Hospitals
- Neurogene hires new CCO as it eyes commercial future for its Rett gene therapy
- Biovac nets $108M finance package to build Africa’s first fully integrated vaccine plant
- Theramex exits self-regulatory body after ‘systemic’ compliance failures
- Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
- Bayer falls short in bid to block J&J’s survival claims in prostate cancer clash
- Biogen bullish on America with Durham Bulls team up
- AbbVie launches ‘PSO Done’ psoriasis campaign with cross-agency effort
- DOJ seeks immediate asset freeze, receivership against telehealth company Zealthy
- New Clues Explain Why Immunotherapy Fails in Pancreatic Cancer
- Does My Child Have a Language Disorder?
- Journalists Talk Hot Health Topics: Urgent Care Clinics Performing Abortions and Doulas’ Pay
- AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
- Tu nuevo terapeuta: conversador, indiscreto… y difícilmente humano
- What the Health? From KFF Health News: A New CDC Nominee, Again
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care
- Oscar unveils Lucie, its one-stop shop for individual market plans, supplemental benefits
- Affordability, transparency: A look at large employers' top healthcare concerns
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- SocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patients
- FDA To Review Whether To Allow More Access To Certain Peptides
- Rising Colon Cancer Deaths Hit Younger Adults Without Degrees Hardest
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Over 80% of PCPs concerned about financial stability over next several years
- Industry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the program
- FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
- Most People Would Take A Blood Test For Alzheimer's, Study Says
- This Sexually Transmitted Infection Linked To Heart Attack, Stroke
- How Playtime at Age 2, Especially with Parents, Shapes Teen Fitness Habits
- New Depression Treatment Matches ECT with Less Memory Loss, Study Says
- Memory Problems? Your Salt Intake Could Make Matters Worse, Study Says
- Ultra-Processed Foods Linked To Fatty Muscles, Potential Knee Arthritis
- Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
- Gen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study finds
- Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
- Remarks at the Options Market Structure Roundtable
- Cattywampus: Statement on the CAT Concept Release
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Beyond the Visit: How AI Companion Technology Is Reshaping Outcomes for Aging Populations
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- Air Pollution and Weather Tied to Migraines
- Brain Cancer Awareness: The Importance of Molecular Testing for Patients with Rare Brain Tumors
- AI simulates real-world HCP feedback on pharma content
Walgreens Boots Alliance Inc. has been supporting their stores with pharmacy profits as they lose a lot of money on their other retail lines. This bodes ill for controlling prescription drug costs in America, and will further challenge inner city residents seeking to fill their prescriptions:
Walgreens plans to close 1,200 stores as it looks for a turnaround
Walgreens’ stock has been hammered this year as consumer shopping patterns have changed, but the company’s latest earnings are getting better reception
By Emily Bary - October 15, 2024Walgreens Boots Alliance Inc. plans to shutter about 1,200 stores over the next three years in a bid to improve earnings.
The retail and pharmacy chain has struggled in recent years as shopping preferences have changed and consumers have moved to buy more products online. Walgreens previously embarked on a cost-cutting plan largely targeting the retail pharmacy business.
Walgreens announced the three-year plan for store closures alongside its earnings Tuesday morning, with the company noting that about 500 of the closures are expected in fiscal year 2025, which just began.
The company expects the move will prove immediately accretive to adjusted earnings per share and free cash flow.
After a deeply disappointing report three months back that brought a guidance cut and ushered in a 22% one-day stock decline, Walgreens’ latest results are getting a better reception on Wall Street. Shares are up 5% in premarket action Tuesday as Walgreens cleared the consensus view on both revenue and earnings.
The results “reflected our disciplined execution on cost management, working capital initiatives and capex reduction,” Chief Executive Tim Wentworth said in a release.
Walgreens’ revenue rose 6% to $37.5 billion, while analysts were looking for $35.8 billion.
The company’s U.S. retail pharmacy business saw a 6.5% sales gain in the quarter as well as an 8.3% rise in comparable sales. Pharmacy sales were up 9.6%, or 11.7% on a comparable-sales basis, reflecting “higher brand inflation and mix impact,” according to Walgreens’ earnings release.
Retail sales fell 3.5%, while comparable retail sales were down 1.7%, “reflecting a challenging retail environment and continued channel shift,” Walgreens said.
The company posted a fiscal fourth-quarter net loss of $3.0 billion, or $3.48 a share, compared with $180 million, or 21 cents a share, in the year-earlier period. The sizable loss included multiple non-cash charges.
On an adjusted basis, Walgreens earned 39 cents a share, while analysts tracked by FactSet were modeling 36 cents a share.
For fiscal 2025, Walgreens models $1.40 to $1.80 in adjusted earnings per share, while the FactSet consensus was for $1.72. The company expects its U.S. healthcare business and international business to grow, while the U.S. retail pharmacy business is anticipated to decline. The company is also looking for $147 billion to $151 billion in fiscal 2025, sales, while analysts were modeling $147.6 billion.
“Fiscal 2025 will be an important rebasing year as we advance our strategy to drive value creation,” Wentworth said. “This turnaround will take time, but we are confident it will yield significant financial and consumer benefits over the long term.”
Walgreens shares are down 66% so far this year.
NPR reporter Alina Selyukh has posted a backgrounder on the troubles at CVS and Walgreen's:
https://www.npr.org/2024/10/16/nx-s1-5154129/cvs-and-walgreens-closing-stores-why
CVS and Walgreens are ailing. Here’s why
By Alina Selyukh - October 16, 2024Not too long after Tim Wentworth became CEO of Walgreens, he revealed a stunning figure: Roughly a quarter of the pharmacy chain’s stores do not make money.
On Tuesday, he said 1,200 of those stores will close over three years. That’s two weeks after rival CVS announced layoffs of 2,900 corporate staff. Both chains are on a multibillion-dollar cost-saving spree — closing hundreds of locations, cutting thousands of jobs and, really, reconsidering their role in Americans’ lives.
The slow simmer of mistakes and misfortunes has come to a boil for the biggest U.S. drugstore chains. They’ve accumulated too many stores at a time of changing shopper habits. They’re saddled with numerous government fines and a particularly ailing relationship with health insurers.
The problem of stores
CVS and Walgreens have some notable differences. Walgreens, which also owns the British drugstore Boots, is more singularly focused on its pharmacy business. CVS has expanded further into health care through mergers with insurer Aetna and Caremark, a pharmacy benefit manager that helps insurers negotiate prescription drug coverage and costs. Yet the two companies have made similar missteps.
The simplest part of the problem is scale. CVS and Walgreens grew massive nationwide footprints of more than 9,000 and 8,000 stores, respectively. They gobbled up mom-and-pop shops and signed long-term leases for prime locations on street corners.
Now, shoppers regularly complain about chronically understaffed stores, with products locked up to prevent theft. The shelves of snacks, makeup, greeting cards and cleaning products were meant to boost profits. But sales have sagged for years — a result of a losing battle with Amazon, Walmart, Costco, grocery and dollar stores.
CVS and Walgreens “probably do have too many stores because they overexpanded, but the bigger problem is that the stores that they have are not very good,” said Neil Saunders, retail analyst at the firm GlobalData.
The chains have failed to add new incentives for shoppers, beyond photo booths and returns drop-off centers, says Anshuman Jaiswal, a longtime consultant to retailers and pharmacies. And neither chain has built a meaningful online presence designed to give customers what they need.
“If you go to CVS.com or Walgreens.com, if you are placing an order for cough syrup, why don't I sell chicken broth as a product recommendation immediately?” Jaiswal says. “It's about reimagining the business model.”
The problem of prescriptions
Given the retail struggles, pharmacies could perhaps simply ditch the convenience store and focus on selling medicine — except CVS and Walgreens say it’s harder and harder to make a profit from this part of their business.
Years ago, a big shift in the power balance between pharmacies and health insurers revealed the limits of drugstores’ leverage.
“Historically, there was a view that there was a lot of customer loyalty to their specific retail pharmacy … and that patients, or consumers, would be all up in arms if they were forced to move their prescriptions,” says Brian Tanquilut, health care services analyst at the investment bank Jefferies.
Walgreens tested this theory about a decade ago when it got into a public fight with Express Scripts, a pharmacy benefit manager that worked with major health insurers.
Walgreens and Express Scripts played a game of chicken over how much Walgreens should earn from prescriptions — and Walgreens lost. For a time, it got kicked out of insurance networks used by millions of people, who simply went elsewhere to get their medicine at the lower in-network prices.
“What that did was to prove that patient loyalty is not to the retail pharmacy, but it actually is whatever my insurance is willing to pay,” Tanquilut says. “And that opened the door for the payers to keep pushing pricing down on retail pharmacy chains.”
Hoping reinvention is the cure
These days, CVS and Walgreens are facing tough competition from pharmacies that don’t depend as much on profits from prescriptions because they’re part of retail giants, including Walmart and Costco. The drugstore chains also have spent millions of dollars on government fines over allegations of unsafe staffing levels, overbilling government insurance programs and contributing to the opioid epidemic.
Over the years, CVS and Walgreens attempted to reframe themselves as health care hubs, expanding primary-care clinics. But these operations cost time and money.
On Tuesday, Walgreens CEO Wentworth said his chain is “reorienting to its legacy strength as a retail pharmacy-led company.” CVS is reportedly weighing a breakup to undo its mergers with Aetna and Caremark.
Both companies are also proposing new structures for how they want to be paid for filling prescriptions, hoping this is the big shot in the arm they need.
"I'm very confident that over a two- to three-year period we will have reset the framework for reimbursement discussions," Wentworth told investors on Tuesday. “We are in the early stages of a turnaround that will take time.”
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














